(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 90.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Verrica Pharmaceuticals's revenue in 2025 is $7,179,000.On average, 3 Wall Street analysts forecast VRCA's revenue for 2025 to be $1,841,495,671, with the lowest VRCA revenue forecast at $1,510,377,916, and the highest VRCA revenue forecast at $2,349,271,222. On average, 2 Wall Street analysts forecast VRCA's revenue for 2026 to be $2,598,071,993, with the lowest VRCA revenue forecast at $2,192,036,534, and the highest VRCA revenue forecast at $3,004,107,453.
In 2027, VRCA is forecast to generate $5,162,847,229 in revenue, with the lowest revenue forecast at $5,162,847,229 and the highest revenue forecast at $5,162,847,229.